{"id":"W2237254160","doi":"10.1056/nejmoa1510016","title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1226,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Cabozantinib; Everolimus; Renal cell carcinoma; Axitinib; Oncology; Medicine; Internal medicine; Urology; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05038606030181386,"score_gpt":0.2971903907800629,"score_spread":0.2468043304782491,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}